Facts About CBD
Cannabidiol (CBD) is one of at least 60 active cannabinoids identified in cannabis. It is a major constituent of the plant, accounting for up to 40% of the plant’s extract, as a non-psychotropic phytocannabinoid. CBD is considered to have a wider scope of medical applications than tetrahydrocannabinol (THC).
CBD is an amazing compound; it can be used to treat chronic pain, anxiety and other mood disorders, as well as being a neuro-protectant and a very promising anti-cancer drug. CBD’s value in treating chronic pain is enhanced over THC because it is non-psychoactive.
CBD works against pain primarily in the peripheral nervous system. It does not work like typical pain meds by effecting the central nervous system; it works at the neuro-synapse. When we sustain injuries, often the pain is acute and disappears completely. Other times we have persistent or intermittent pain; however, with many disorders the pain is either part of the underlying problem itself (multiple sclerosis, rheumatoid arthritis, etc.) or the pain becomes a syndrome of its own.
In a recent Scientific American article, chronic pain and CBD is discussed; when an injury takes place, increased glial cell production forms around the neuro junctions. These glial cells produce cytokines which are the chemical transmitters that spread inflammation and signal pain. When a molecule of CBD binds to the glial cell, the cytokine production decreases and the patient feels a marked decrease in pain. This would also explain why some patients have pain relief that lasts far beyond the theoretical effect of the CBD.
CBD Treatment in the News:
“By the time she was 3, Charlotte was having up to 300 grand mal seizures every week. Eventually she lost the ability to walk, talk and eat. Her father, Matt Figi, found a similar case online in which medical marijuana helped a boy’s seizures. The family decided to give it a try. The first time Paige Figi gave her daughter, Charlotte, cannabis oil, the child’s seizures stopped for seven days.
Read More on Article on CNN: http://www.cnn.com/2013/08/07/health/charlotte-child-medical-marijuana/
CBD Clinical Study from the National Center for Biotechnology Information:
Cannabidiol provides long-lasting protection against the deleterious effects of inflammation in a viral model of multiple sclerosis
Inflammation in the central nervous system (CNS) is a complex process that involves a multitude of molecules and effectors, and it requires the transmigration of blood leukocytes across the blood-brain barrier (BBB) and the activation of resident immune cells. Cannabidiol (CBD), a non-psychotropic cannabinoid constituent of Hemp, has potent anti-inflammatory and immunosuppressive properties. Yet, how this compound modifies the deleterious effects of inflammation in TMEV-induced demyelinating disease (TMEV-IDD) remains unknown.
Using this viral model of multiple sclerosis (MS), we demonstrate that CBD decreases the transmigration of blood leukocytes by downregulating the expression of vascular cell adhesion molecule-1 (VCAM-1), chemokines (CCL2 and CCL5) and the proinflammatory cytokine IL-1β, as well as by attenuating the activation of microglia. Moreover, CBD administration at the time of viral infection exerts long-lasting effects, ameliorating motor deficits in the chronic phase of the disease in conjunction with reduced microglial activation and pro-inflammatory cytokine production.
Adenosine A2A receptors participate in some of the anti-inflammatory effects of CBD, as the A2A antagonist ZM241385 partially blocks the protective effects of CBD in the initial stages of inflammation.
Together, our findings highlight the anti-inflammatory effects of CBD in this viral model of MS and demonstrate the significant therapeutic potential of this compound for the treatment of pathologies with an inflammatory component.